| Not Yet Recruiting | HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer NCT07425054 | Jennifer Dorth | Phase 2 |
| Recruiting | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers NCT05639972 | Christian Hinrichs | Phase 1 / Phase 2 |
| Recruiting | PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cerv NCT06157151 | Precigen, Inc | Phase 2 |
| Recruiting | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes NCT06640283 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Yea NCT06756269 | Shanghai Bovax Biotechnology Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 NCT06454175 | Shanghai Bovax Biotechnology Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese M NCT06465914 | Shanghai Bovax Biotechnology Co., Ltd. | Phase 3 |
| Active Not Recruiting | IBRX-042 In Participants With HPV-Associated Tumors NCT05976828 | ImmunityBio, Inc. | Phase 1 |
| Active Not Recruiting | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) NCT05973487 | TScan Therapeutics, Inc. | Phase 1 |
| Recruiting | Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC) NCT06305676 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Active Not Recruiting | Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer NCT06234748 | University of Michigan Rogel Cancer Center | Phase 2 |
| Enrolling By Invitation | Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7 NCT06508138 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years NCT06041061 | Sinocelltech Ltd. | Phase 3 |
| Unknown | Radiosensitivity of HPV-related Tumors: Towards a Genomic Approach NCT06321627 | European Institute of Oncology | — |
| Active Not Recruiting | A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) NCT05814549 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers NCT05686226 | Christian Hinrichs | Phase 2 |
| Recruiting | Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithel NCT06574087 | PCK Marine Hospital in Gdynia | N/A |
| Recruiting | A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Ch NCT05262010 | National Vaccine and Serum Institute, China | Phase 3 |
| Recruiting | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With H NCT05307939 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV NCT05247853 | Montefiore Medical Center | — |
| Unknown | Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and NCT04920526 | Kenya Medical Research Institute | — |
| Terminated | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Sele NCT05061940 | Repertoire Immune Medicines | — |
| Unknown | A Tailored, Health Communication Intervention for HPV Vaccine Hesitant Families NCT04380623 | Meharry Medical College | N/A |
| Recruiting | Detecting HPV DNA in Anal and Cervical Cancers NCT04857528 | University of Chicago | — |
| Completed | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma NCT03795610 | Assuntina G. Sacco, MD | Phase 2 |
| Withdrawn | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients NCT04001413 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma NCT03978689 | Cue Biopharma | Phase 1 |
| Completed | HPV in Blood Samples From Cervical Cancer Patients. NCT03749720 | University of Aarhus | N/A |
| Unknown | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors NCT03475953 | Institut Bergonié | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers NCT03260023 | Transgene | Phase 1 / Phase 2 |
| Completed | Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings NCT03033550 | Boston Medical Center | N/A |